THERAPEUTIC PLASMA EXCHANGE
Targeted removal of pathogenic plasma components under medical supervision
Therapeutic Plasma Exchange (TPE) is a hospital-grade apheresis procedure used to selectively remove circulating plasma components implicated in disease and biological dysfunction. At Reborne Longevity, TPE is delivered within a strictly governed medical framework and prescribed only following comprehensive clinical assessment.
Conditions we treat include :
Moderate Alzheimers, Autoimmune Conditions, Elevated Lipoprotein (a)
Clinical Rationale
Plasma acts as a transport medium for antibodies, inflammatory mediators, lipoproteins, and misfolded proteins. In selected clinical contexts, these circulating factors may contribute directly to disease progression. TPE physically removes these components, reducing biological burden where clinically justified.
How the Process Works
Blood is withdrawn via venous access and processed through a certified apheresis system that separates plasma from cellular components. Plasma is removed and replaced with appropriate solutions before cellular elements are returned to circulation.
.png)
Frequently Asked Questions About Genetic Testing
TPE Pathway: Autoimmune & Immune-Mediated Disorders
Clinical Rationale
Autoimmune conditions are often driven by circulating autoantibodies and immune complexes. TPE has an established role in conventional medicine for rapidly reducing immune burden in antibody-mediated disease.
Clinical Evidence – Clustered
International guidelines recognise TPE as a first-line or adjunctive therapy in selected autoimmune and neurological conditions.
Key references:
Schwartz J et al., J Clin Apher 2016 (PMID 27373620).
Kaplan AA, Am J Kidney Dis 2001 (PMID 11136168).
Evidence Snapshot – Mobile
TPE is an established therapy for antibody-mediated autoimmune disease.
TPE Pathway: Alzheimer’s Disease – Amyloid Burden (Moderate Stage)
Clinical Rationale
Amyloid-β exists in equilibrium between plasma and the central nervous system. Reducing circulating amyloid may support redistribution from the brain via the peripheral sink mechanism.
Clinical Evidence – Clustered
Clinical trials have explored plasma exchange with albumin replacement in Alzheimer’s disease, demonstrating biological effects on amyloid dynamics.
Key references:
Boada M et al., Alzheimers Dement 2020 (PMID 33010943).
Sagare AP et al., Nat Rev Neurol 2012 (PMID 22373772).
Evidence Snapshot – Mobile
TPE has been studied for its effects on circulating amyloid dynamics in Alzheimer’s disease.
TPE Pathway: Elevated Lipoprotein(a) [Lp(a)]
Clinical Rationale
Lipoprotein(a) is a genetically determined cardiovascular risk factor resistant to most lifestyle and pharmacological interventions. Plasma exchange can acutely reduce circulating Lp(a).
Clinical Evidence – Clustered
Lipoprotein apheresis literature supports the reduction of Lp(a) in selected high-risk patients.
Key references:
Moriarty PM et al., J Clin Lipidol 2019 (PMID 30905661).
Tsimikas S, J Am Coll Cardiol 2017 (PMID 28183486).
Evidence Snapshot – Mobile
Apheresis techniques can significantly reduce circulating Lp(a) in selected patients.